Chitin nanofibrils suppress skin inflammation in atopic dermatitis-like skin lesions in NC/Nga mice

Carbohydrate Polymers

Volumn 146, Issue , 2016, Pages 320-327

  Izumi, Ryotaro ^a   Azuma, Kazuo ^a   Izawa, Hironori ^a   Morimoto, Minoru ^a   Nagashima, Masaaki ^a   Osaki, Tomohiro ^a   Tsuka, Takeshi ^a   Imagawa, Tomohiro ^a   Ito, Norihiko ^a   Okamoto, Yoshiharu ^a   Saimoto, Hiroyuki ^a   Ifuku, Shinsuke ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Atopic dermatitis; Chitin nanofibril; Corticosteroids; Cyclooxygenase 2; Inducible nitric oxide synthase; Nuclear factor kappa B

Indexed keywords

CHITIN; DERMATOLOGY; DRUG PRODUCTS; NANOFIBERS; NITRIC OXIDE; PATHOLOGY;

ATOPIC DERMATITIS; CORTICOSTEROIDS; CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; NANOFIBRIL; NUCLEAR FACTOR KAPPAB;

DERMATITIS;

CHITIN; NANOFIBER;

ANIMAL; ATOPIC DERMATITIS; CHEMISTRY; DRUG EFFECTS; INFLAMMATION; MOUSE; SKIN;

ANIMALS; CHITIN; DERMATITIS, ATOPIC; INFLAMMATION; MICE; NANOFIBERS; SKIN;

EID: 84962888818     PISSN: 01448617     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carbpol.2016.03.068     Document Type: Article

References (43)

1. M. Anraku, R. Tabuchi, S. Ifuku, T. Ishiguro, D. Iohara, and F. Hirayama Surface-deacetylated chitin nano-fiber/hyaluronic acid composites as potential antioxidative compounds for use in extended-release matrix tablets Int. J. Mol. Sci. 16 2015 24707 24717
2. K. Azuma, S. Ifuku, T. Osaki, Y. Okamoto, and S. Minami Preparation and biomedical applications of chitin and chitosan nanofibers Journal of Biomedical Nanotechnology 10 2014 2891 2920
3. K. Azuma, T. Osaki, S. Ifuku, H. Saimoto, T. Tsuka, T. Imagawa, and et al. α-Chitin nanofibrils improve inflammatory and fibrosis responses in mice with inflammatory bowel disease Carbohydrate Polymers 90 2012 197 200
4. K. Azuma, T. Osaki, S. Kurozumi, M. Kiyose, T. Tsuka, Y. Murahata, and et al. Anti-inflammatory effects of orally administered glucosamine oligomer in an experimental model of inflammatory bowel disease Carbohydrate Polymers 22 2015 448 456
5. M.J. Bae, H.S. Shin, E.K. Kim, J. Kim, and D.H. Shon Oral administration of chitin and chitosan prevents peanut-induced anaphylaxis in a murine food allergy model International Journal of Biological Macromolecules 61 2013 164 168
6. P.J. Barnes, and M. Karin Nuclear factor-kappa B: a pivotal transcription factor in chronic inflammatory diseases New England Journal of Medicine 336 1997 1066 1071
7. J. Callen, S. Chamlin, L.F. Eichenfield, C. Ellis, M. Girardi, M. Goldfarb, and et al. A systematic review of the safety of topical therapies for atopic dermatitis British Journal of Dermatology 156 2008 203 222
8. C.A. Da Silva, C. Chalouni, A. Williams, D. Hartl, C.G. Lee, and J.A. Elias Chitin is a size-dependent regulator of macrophage TNF and IL-10 production Journal of Immunology 182 2009 3573 3582
9. Y. Ding, D. Chen, A. Tarcsafalvi, R. Su, L. Qin, and J.S. Bromberg Suppressor of cytokine signaling 1 inhibits IL-10-mediated immune responses Journal of Immunology 170 2003 1383 1391
10. A.K. Dutta, H. Izawa, M. Morimoto, H. Saimoto, and S. Ifuku Fiber width and molecular weight studies of a-chitin nanofibers Journal of Chitin and Chitosan Science 1 2013 192 196
11. L.F. Eichenfield, W.L. Tom, T.G. Berger, A. Krol, A.S. Paller, K. Schwarzenberger, and et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies Journal of American Academy of Dermatology 71 2014 116 132
12. C.O. Elson, Y. Cong, V.J. McCracken, R.A. Dimmitt, R.G. Lorenz, and C.T. Weaver Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota Immunological Reviews 206 2005 260 276
13. D. Harada, C. Takada, Y. Nosaka, Y. Takashima, K. Kobayashi, K. Takada, and et al. Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models International Immunopharmacology 9 2009 55 62
14. U.R. Hengge, T. Ruzicka, R.A. Schwartz, and M.J. Cork Adverse effects of topical glucocorticosteroids Journal of American Academy of Dermatology 54 2006 1 15
15. S. Ifuku Chitin and chitosan nanofibers: preparation and chemical modifications Molecules 19 2014 18367 18380
16. S. Ifuku, M. Nogi, K. Abe, M. Yoshioka, M. Morimoto, H. Saimoto, and et al. Preparation of chitin nanofibers with a uniform width as alpha-chitin from crab shells Biomacromolecules 10 2009 1584 1588
17. S. Ifuku, and H. Saimoto Chitin nanofibers: preparations, modifications, and applications Nanoscale 4 2012 3308 3318
18. I. Ito, T. Osaki, S. Ifuku, H. Saimoto, Y. Takamori, S. Kurozumi, and et al. Evaluation of the effects of chitin nanofibrils on skin function using skin models Carbohydrate Polymers 101 2014 464 470
19. R. Izumi, S. Komada, K. Ochi, L. Karasawa, T. Osaki, Y. Murahata, and et al. Favorable effects of superficially deacetylated chitin nanofibrils on the wound healing process Carbohydrate Polymers 123 2015 461 467
20. T. Karrasch, and T. Jobin NF-κB and the intestine: friend or foe? Inflammatory Bowel Disease 14 2008 114 124
21. S. Kharitonov, D. Yates, R.A. Robbins, R. Logan-Sinclair, E.A. Shinebourne, and P.J. Barnes Increased nitric oxide in exhaled air of asthmatic patients The Lancet 343 1994 133 135
22. A. Kubo, K. Nagao, M. Yokouchi, H. Sasaki, and M. Amagai External anti-gen uptake by Langerhans cells with reorganization of epidermal tight junctionbarriers The Journal of Experimental Medicine 13 2009 2937 2946
23. P. Luca, and M. Perretti Advances in the pathophysiology of constitutive and inducible cyclooxygenases two enzymes in the spotlight Biochemical Pharmacology 65 2003 153 159
24. H. Matsuda, N. Watanabe, G.P. Geba, J. Sperl, M. Tsudzuki, J. Hiroi, and et al. Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice International Immunology 9 1997 461 466
25. E. Mooney, M. Rademaker, R. Dailey, B.S. Daniel, C. Drummond, G. Fischer, and et al. Adverse effects of topical corticosteroids in paediatric eczema: Australasian consensus statement Australasian Journal of Dermatology 56 2015 241 251
26. P. Morganti, and G. Morganti Chitin nanofibrils for advanced cosmeceuticals Clinical Dermatology 26 2008 334 340
27. P. Morganti, R.A.A. Muzzarelli, and C. Muzzarelli Multifunctional use of innovative chitin derivatives for skin care Journal of Applied Cosmetology 24 2006 105 114
28. H. Nakamura, M. Aoki, K. Tamai, M. Oishi, T. Ogihara, Y. Kaneda, and et al. Prevention and regression of atopic dermatitis by ointment containing NF-kappaB decoy oligodeoxynucleotides in NC/Nga atopic mouse model Gene Therapy 9 2002 221 1229
29. K. Nishimura, S. Nishimura, N. Nishi, I. Saiki, S. Tokura, and I. Azuma Immunological activity of chitin and its derivatives Vaccine 2 1984 93 99
30. J.A. Odhiambo, H.C. Williams, T.O. Clayton, C.F. Robertson, M.I. Asher, and ISAAC Phase Three Study Group Global variations in prevalence of eczema symptoms in children from ISAAC phase three Journal of Allergy and Clinical Immunology 124 2009 1251 1258
31. A.W. Rawlings, and C.R. Harding Moisturization and skin barrier function Dermatologic Therapy 17 2004 43 48
32. A.J. Schottelius, M.W. Mayo, R.B. Sartor, and A.S. Baldwin Jr. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding Journal of Biological Chemistry 274 1999 31868 31874
33. T. Seene, P. Kaasik, A. Pehme, K. Alev, and E.M. Riso The effect of GCs on the myosin heavy chain isoforms turnover in skeletal muscle Journal of Steroid Biochemistry and Molecular Biology 86 2003 201 206
34. Y. Shibata, L.A. Foster, J.F. Bradfield, and Q.N. Myrvik Oral administration of chitin down-regulates serum IgE levels and lung eosinophilia in the allergic mouse Journal of Immunology 164 2000 1314 1321
35. T. Shiohara, J. Hayakawa, and Y. Mizukawa Animal models for atopic dermatitis: are they relevant to human disease? Journal of Dermatological Science 36 2004 1 9
36. R. Sidbury, and J.M. Hanifin Systemic therapy of atopic dermatitis Clinical and Experimental Dermatology 25 2000 559 566
37. A. Sugiyama, S. Hata, K. Suzuki, E. Yoshida, R. Nakano, S. Mitra, and et al. Oral administration of paramylon, a beta-1,3-d-glucan isolated from Euglena gracilis Z inhibits development of atopic dermatitis-like skin lesions in NC/Nga mice Journal of Veterinary Medical Science 72 2010 755 763
38. A. Tanaka, S. Muto, K. Jung, A. Itai, and H. Matsuda Topical application with a new NF-kappaB inhibitor improves atopic dermatitis in NC/NgaTnd mice Journal of Investigate Dermatology 127 2007 855 863
39. Y. Taniguchi, K. Kohno, S. Inoue, S. Koya-Miyata, I. Okamoto, N. Arai, and et al. Oral administration of royal jelly inhibits the development of atopic dermatitis-like skin lesions in NC/Nga mice International Immunopharmacology 3 2003 1313 1324
40. Y. Tomimori, Y. Tanaka, M. Goto, and Y. Fukuda Repeated topical challenge with chemical antigen elicits sustained dermatitis in NC/Nga mice in specific-pathogen-free condition Journal of Investigative Dermatology 124 2005 19 24
41. T. Watanabe, K. Hamada, A. Tategaki, H. Kishida, H. Tanaka, M. Kitano, and et al. Oral administration of lactic acid bacteria isolated from traditional South Asian fermented milk 'dahi' inhibits the development of atopic dermatitis in NC/Nga mice Journal of Nutritional Science and Vitaminology (Tokyo) 55 2009 271 278
42. H. Williams, A. Stewart, E. von Mutius, W. Cookson, H.R. Anderson, and International study of asthma and allergies in childhood (ISAAC) Phase One and Three Study Groups Is eczema really on the increase worldwide? Journal of Allergy and Clinical Immunology 121 2008 947 954
43. Y. Yamamoto, and R.G. Gaynor Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer Journal of Clinical Investigation 107 2001 135 142